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Introduction: Peak and trough serum concentrations of vancomycin were determined in term newborn infants with confirmed
or suspected Staphylococcus sp sepsis by high performance liquid chromatography and flourescence polarization immunoassay.
Objective: To statistically compare the results of the high performance liquid chromatography and flourescence polarization
immunoassay techniques for measuring serum vancomycin concentrations.
Methods: Eighteen peak and 20 trough serum samples were assayed for vancomycin concentrations using high performance
liquid chromatography and flourescence polarization immunoassay from October 1995 to October 1997.
Results: The linear correlation coefficients for high performance liquid chromatography and flourescence polarization
immunoassay were 0.27 (peak, P = 0.110) and 0.26 (trough, P = 0.1045) respectively, which were not statistically significant.
Conclusion: There was wide variation in serum vancomycin concentrations determined by high performance liquid
chromatography as compared with those determined by flourescence polarization immunoassay. There was no recognizable pattern
in the variability; in an apparently random fashion, the high performance liquid chromatography measurement was sometimes
substantially higher than the flourescence polarization immunoassay measurement, and at other times it was substantially lower.
DESCRIPTORS: Chromatography, high pressure liquid. Fluorescence polarization immunoassay. Vancomycin. Sepsis.
Newborn infant.
The rising incidence of nosocomial
methicillin-resistant Staphylococcal sp
infections in intensive care units has re-
sulted in the widespread use of vanco-
mycin, which is a potentially ototoxic
and nephrotoxic when serum concen-
trations are not kept within narrow
therapeutic ranges (peak concentra-
tions between 20-40 µg/ml and trough
between 5-10 µg/mL)1-3. This toxicity
is of particular concern in newborns
and patients with kidney diseases, liver
diseases, and neoplasias, since they
normally receive other nephrotoxic
drugs that may potentiate vancomycin
effects. In these groups of patients,
vancomycin monitoring is routinely
performed to minimize risks4-6.
Two techniques were compared in
the present study: flourescence polar-
ization immunoassay (FPIA) (TDX /
Abbott), and high performance liquid
chromatography (HPLC). FPIA is
more commonly used in clinical labo-
ratories due to the ease of performance,
tiny serum volumes required, rapidity,
and lower cost in comparison to HPLC.
However, there are some reports on the
existence of an inactive vancomycin
metabolite that is not distinguished by
FPIA, while it is separately evaluated
by HPLC. This metabolite has been
found in patients undergoing peritoneal
dialysis8,9. Its serum concentration, as
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well as its depuration, depends mainly
on the half-life of vancomycin in the
circulation and on blood pH. Conse-
quently, although FPIA employs
monoclonal antibodies directed to van-
comycin, this technique could possibly
overestimate vancomycin concentra-
tions in specific groups of patients7.
We compared peak and trough se-
rum vancomycin concentrations as
measured by FPIA and HPLC and
evaluated their association with regard
to clinical efficacy and toxicity.
PATIENTS AND METHODS
Twenty term newborn infants (ges-
tational age 37 to 42 weeks) receiving
vancomycin due to a confirmed or pre-
sumed Staphylococcal sp sepsis, were
enrolled in the study from October
1995 to October 1997.
Diagnostic criteria for neonatal sep-
sis were based on clinical evaluation10,
presence of hypothermia, fever, respi-
ratory distress (tachypnea, grunting,
apnea), cyanosis, tachycardia, poor
feeding, gastric residue, and abdominal
distension. Newborns presenting with
renal failure or receiving other poten-
tially nephrotoxic drugs such as
amikacin, amphotericin B, furosemide,
or indomethacin11 were excluded. Van-
comycin doses were determined ac-
cording to the recommendations of
Young and Mangun12, as well as ac-
cording to gestational age. Vancomy-
cin was diluted in a 5% dextrose wa-
ter solution, and administration oc-
curred over a 60-minute period, con-
trolled by an infusion pump. Seventy-
two hours after the onset of treatment,
two 0.5 mL blood samples and two 1.0
mL blood samples were used to deter-
mine vancomycin concentration by
FPIA and HPLC, respectively. Peak
samples were obtained 1 hour after an-
tibiotic infusion, and trough samples
were obtained 1 hour before the next
infusion. FPIA was performed accord-
ing to the manufacturer’s instructions,
and HPLC was performed using a
Shimadzu 6 A model chromatographic
apparatus with a 230 nm UV detector,
CLC-ODS 150 X 6 mm reverse phase
column (0.05 M, pH 4.6 phosphate-
buffer mobile phase, methanol, aceto-
nitrile 80:15:5) with a 0.8 mL/min flux.
RESULTS
The studied population consists of
20 term newborn infants receiving van-
comycin. Table 1 shows the descriptive
statistics (mean + SD, median, mini-
mum, and maximum) of the param-
eters measured.
Table 2 lists the descriptive statis-
tics (mean + SD, median, minimum,
and maximum) of the doses used and
the gestational ages of the infants.
Table 3 shows the analysis of con-
cordance of the finding of normality—
the adequacy of serum concentrations
achieved— for peak serum vancomy-
cin concentrations as determined by
the FPIA method compared with the
finding of normality by the HPLC
method. There was no statistically sig-
nificant concordance (as determined by
the McNemar test, P = 0.4531) regard-
ing normality of peak concentrations of
serum vancomycin between the FPIA
and HPLC methods.
Table 4 shows the analysis of con-
cordance of the finding of normality for
trough serum vancomycin concentra-
tions as determined by the FPIA method
compared with the finding of normality
Table 1 - Descriptive measures of variables referred to peak (µg/mL) and trough (µg/mL) vancomycin
concentrations by FPIA and HPLC in term newborn infants.
Variable Mean ± SD Median Minimum Maximum n
FPIA peak 23.01 ± 11.45 25.0 2.60 51.0 23
FPIA trough 9.68 ± 15.78 8.30 2.70 25.0 24
HPLC peak 18.26 ± 12.29 17.0 2.60 52.70 21
HPLC trough 9.54 ± 17.12 7.20 1.60 26.0 22
Peak difference 5.99 ± 11.20 6.20 - 23.80 21.50 17
Trough difference 1.96 ± 16.69 2.40 - 19.30 14.90 20
Table 2 - Descriptive measures of variables referred to dose (mg/kg/d) and gestational age in weeks.
Variable Mean ± SD Median Minimum Maximum n
Dose 44.36 + 6.50 45 32 60 25
Gestational Age 42 4/7 + 3 42 37 6/7 47 25
Table 3 - Concordance of normality of peak vancomycin concentrations (20-40 µg/mL) evaluated by
FPIA and HPLC (McNemar test, P = 0.4531).
FPIA
HPLC Adequate Inadequate Total
n (%) n (%) n (%)
Adequate 5 (27.8) 2 (11.1) 7 (38.9)
Inadequate 5 (27.8) 6 (33.3) 11 (61.1)
Total 10 (55.6) 8 (44.4) 18 (100.0)
Table 4 - Concordance of normality of trough vancomycin concentrations (5-10 µg/mL) evaluated
by FPIA and HPLC (McNemar test, P = 0.7266).
FPIA
HPLC Adequate Inadequate Total
n (%) n (%) n (%)
Adequate 4 (20.0) 3 (15.0) 7 (35.0)
Inadequate 5 (25.0) 8 (40.0) 13 (65.0)
Total 9 (45.0) 11 (55.0) 20 (100.0)
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by the HPLC method. There was no sta-
tistically significant concordance (as
determined by the McNemar test, P =
0.7266) regarding normality of trough
concentrations of serum vancomycin
between the FPIA and HPLC methods.
Figure 1 shows the linear correla-
tion between peak serum vancomycin
concentrations as determined by the
FPIA and HPLC methods. The linear
correlation was r2 = 0.27, P = 0.1110.
A wide variation exists in the correla-
tions, with points scattered widely on
both sides of a hypothetical 1:1 regres-
sion line. In an apparently random pat-
tern, HPLC measurements were some-
times higher than FPIA measurements
and sometimes lower.
Figure 2 shows the linear correla-
tion between trough serum vancomy-
cin concentrations as determined by
the FPIA and HPLC methods. The lin-
ear correlation was r2 = 0.26, P =
0.1045). A wide variation exists in the
correlations, with points scattered
widely on both sides of a hypothetical
1:1 regression line. In an apparently
random pattern, HPLC measurements
were sometimes higher than FPIA
measurements and sometimes lower.
DISCUSSION
There are a few prospective studies
on monitoring of vancomycin in new-
born infants, and in most cases they
used the FPIA method. It is accepted
that initial doses of vancomycin should
be calculated on the basis of
postconceptual age and body weight.
Dose corrections are afterwards made
by monitoring of serum concentrations
of vancomycin13. This practice de-
creases drug toxicity and also the use of
insufficient dosages, thus favoring new-
born infant’s successful treatment. How-
ever, measured vancomycin concentra-
tions may be dramatically affected by
the method used; FPIA is less time con-
suming but has the disadvantage of
overestimating drug concentrations due
to the presence of an inactive metabo-
lite that is detected together with the in-
tact drug, even though a monoclonal
antibody is employed in this commer-
cial kit7,8. This problem has not yet been
reported concerning HPLC, which is
unfortunately a methodology that is not
feasible in a clinical laboratory. In our
study, we were unable to use HPLC
clinically, so dose modifications were
based on FPIA results.
When normality (adequate serum
concentrations of vancomycin) was
correlated for FPIA vs. HPLC, we did
not find statistically significant corre-
lations for either peak or trough con-
centrations.
We also did not find a statistically
significant linear correlation of the
FPIA vs HPLC methods for either peak
or trough serum concentrations of van-
comycin.
CONCLUSION
Monitoring of serum concentra-
tions of vancomycin is mandatory for
monitoring vancomycin therapy in
Figure 1 - Linear correlation between peak vancomycin concentrations by FPIA and HPLC.
Figure 2 - Linear correlation between trough vancomycin concentrations by FPIA and HPLC.
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both term and premature newborn in-
fants, since in these patients there are
rapid and intermittent changes in body
water composition and renal clearance
that interfere with drug kinetics, distri-
bution, metabolism, and depuration.
When interpreting the results of serum
vancomycin concentration assays, neo-
natologists should consider the advan-
tages and disadvantages of each
method; FPIA possibly overestimates
concentrations in certain cases, and
HPLC is not a feasible method in clini-
cal laboratories. However, whatever the
method chosen, it is important to high-
light that the present study showed a
lack of linear correlation between
FPIA and HPLC for both peak and
trough vancomycin concentrations.
RESUMO RHCFAP/3052
FEFERBAUM R e col. -
Monitorização do vale e pico sérico
de vancomicina em recém-nascidos
de termo: comparação entre as
técnicas de cromatografia líquida
de alta eficácia e imunoensaio por
fluorescência polarizada. Rev.
Hosp. Clín. Fac. Med. S. Paulo
56(5):149-152, 2001.
Introdução: Foi realizada monito-
rização dos níveis séricos de vanco-
micina em recém-nascidos de termo
com sepse ou suspeita de sepse
Staphylococcus sp., através da croma-
tografia líquida de alta eficácia (HPLC)
e imunoensaio por fluorescência pola-
rizada (FPIA).
Objetivo: Verificar a existência de
correlação estatística entre os resulta-
dos obtidos pelas duas técnicas.
Método e casuística: Foram obti-
das dezoito e vinte concentrações
séricas de vancomicina no pico e vale
respectivamente, em recém-nascidos
de termo, no período de outubro de
1995 a outubro de 1997.
Resultado: O coeficiente de corre-
lação linear para pico sérico foi de
0,27, p=0,110 e para vale sérico 0,26,
p= 0,1045 não sendo estatisticamente
significativo, não sendo estatisticamen-
te significativo.
Conclusão: Apesar da pequena
casuística, não houve correlação esta-
tisticamente significante entre os resul-
tados obtidos pelos duas técnicas.
DESCRITORES : Cromatografia
de alta eficácia. Imunoensaio por
fluorescência Polarizada. Vanco-
micina. Sepse. Recém-nascido.
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